Latham Named Life Sciences Practice Group of the Year

Latham has been recognized as Life Sciences Group of the Year by Law360 for precedent-setting court wins, landmark transactions, and regulatory victories that have transformed the life sciences industry.

In its published profile, Law360 referenced Latham’s “considerable depth and breadth of experience” in life sciences and the industry group’s ability to represent companies through every part of their life cycle.

“We really have built a one-stop shop for all of those things,” Shayne Kennedy, Global Chair of Latham's Healthcare & Life Sciences Industry Group told Law360. “We have those capabilities at the highest levels across all of those areas, we are No. 1.”

The profile referenced Latham’s representation of Prometheus Biosciences Inc. in its US$10.8 billion acquisition by Merck & Co. Inc and Mineralys Therapeutics Inc.'s US$192 million IPO, as well as success in the courtroom including the firm’s precedent-setting Federal Circuit win for Avadel Pharmaceuticals PLC in which the Federal Circuit — for the first time in history — affirmed a district court decision ordering the delisting of an Orange Book patent, among others.

John Manthei, Global Chair of Latham's Healthcare & Life Sciences Practice credits the firm’s success in the sector to a collaborative and cross-practice approach to addressing client needs.

“Each one of those achievements required multiple disciplines, it wasn't like any one area of the firm operating on its own,” Manthei told Law360. “Each one of those required attorneys from multiple practice areas to be able to drive that success.”

Along with Life Sciences, Law360 recognized Latham as Practice Group of the Year for Cybersecurity & Privacy, Energy, Fintech, Mergers & Acquisitions, and Securities in 2023.